US regulators approve Takeda's Orzeyful for a type of narcolepsy
Takeda's orexin agonist Orzeyful (oveporexton) received US national regulatory approval in August 2026 for a type of narcolepsy. The drug is approved only for that specific type of narcolepsy, not all sleep disorders. Broader uses, such as ADHD, are still investigational, and long-term outcomes are not yet established.
Why it matters
People with narcolepsy need more treatment options, and the approval of an orexin agonist introduces a new mechanism of action for the condition.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news